A Phase 4 interventional study of SGLT2 inhibitors (Dapagliflozin and Empagliflozin) in Atrial Fibrillation, SGLT2 Inhibitor and DC Cardioversion, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing SGLT2 inhibitors in Atrial Fibrillation — 9 open to participants now, 10 under way, 5 of them phase 3. A drug class: SGLT2 inhibitors · Atrial Fibrillation.
Among the 15 studies testing SGLT2 inhibitors in Atrial Fibrillation, this one is the 9th largest by planned enrollment, is one of 4 that started in 2024, is one of 5 in phase 4, and was the 15th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →9 of the 15 studies testing SGLT2 inhibitors in Atrial Fibrillation are open now, in 7 countries. Recruiting first, the newest first:
Region Stockholm · Sites in Sweden
Ages 55+
Yonsei University · Sites in Korea, Republic of
Ages 19–84
Huashan Hospital · Sites in China
Ages 18–80
University of East Anglia · Sites in United Kingdom
Ages 18+
Region Örebro County · Sites in Czechia, Denmark, Sweden
Ages 18+
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 6 · Phase 4 5
First in 2021; this study’s year is marked. 4 started in 2024.
This study's planned enrollment of 200 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 280 across the 15 interventional studies. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 10 most frequent:
Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
16 studies in Atrial Fibrillation by Samsung Medical Center: 7 open now, 7 under way, none of them phase 3. Of 6 finished, 0 (0%) have results posted.
Among the 16 studies in Atrial Fibrillation by Samsung Medical Center, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2024, is one of 2 in phase 4, and was the 15th registered.
Samsung Medical Center’s Atrial Fibrillation studies by the year they started, since 2005.
5 of the studies testing SGLT2 inhibitors in Atrial Fibrillation that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06111443Phase 3Chang Gung Memorial HospitalEffect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation | 2026-11-30 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT07482020Huashan HospitalSGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism | 2026-12-30 |
| NCT06528262Yonsei UniversityEffect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation | 2027-05-31 |
| NCT07776054Samsung Medical CenterClinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 15 studies testing SGLT2 inhibitors in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Samsung Medical Center’s 16 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.
Patients with persistent atrial fibrillation who meet HFpEF diagnostic criteria (H2FPEF ≥6 or HFA-PEFF ≥5) are screened. After at least 4 weeks of anticoagulation and exclusion of intracardiac thrombus by transesophageal echocardiography, electrical cardioversion is performed with a biphasic defibrillator. Patients who restore sinus rhythm and provide written informed consent are randomized 1:1, stratified by AF duration and left atrial size. All patients receive anticoagulation and antiarrhythmic drugs for 1 month per current guidelines, at the discretion of the treating physician. The primary endpoint is recurrence of atrial tachyarrhythmia at 1 month, assessed by 12-lead ECG or continuous monitoring (≥30 seconds). Analyses follow the intention-to-treat principle, with per-protocol analysis as a sensitivity analysis. The sample size of 200 provides approximately 90% power at a two-sided alpha of 0.05 to detect a difference in recurrence (24% vs 47%).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients receive an SGLT2 inhibitor (empagliflozin or dapagliflozin) after successful DC cardioversion, in addition to guideline-directed anticoagulation and antiarrhythmic drugs for 1 month.
Drug: SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
Patients receive guideline-directed anticoagulation and antiarrhythmic drugs after DC cardioversion, without an SGLT2 inhibitor.
Drug page: SGLT2 inhibitorsStudies of SGLT2 inhibitorsSGLT2 inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients receive an SGLT2 inhibitor (empagliflozin or dapagliflozin) after successful DC cardioversion, in addition to guideline-directed anticoagulation and antiarrhythmic drugs for 1 month.
Recurrence of atrial tachyarrhythmia
Composite of atrial fibrillation, atrial flutter, and atrial tachycardia, documented on 12-lead ECG or as an episode lasting ≥30 seconds on continuous ECG monitoring.
Time frame: 1 month after randomization (±1 week)
Recurrence of atrial fibrillation
atrial fibrillation documented on 12-lead ECG or as an episode lasting ≥30 seconds on continuous ECG monitoring.
Time frame: 1 month after randomization (±1 week)
Recurrence of atrial flutter
atrial flutter documented on 12-lead ECG or as an episode lasting ≥30 seconds on continuous ECG monitoring.
Time frame: 1 month after randomization (±1 week)
Recurrence of atrial tachycardia
atrial tachycardia documented on 12-lead ECG or as an episode lasting ≥30 seconds on continuous ECG monitoring.
Time frame: 1 month after randomization (±1 week)
Stroke
Time frame: 1 month after randomization (±1 week)
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Aug 2027, 42 months after the start.
Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 42 months is below that.
Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SGLT2 inhibitors